JTV519 and S107 were proposed to treat CPVT by enhancing the binding of FKBP12.6 to the mutant RyR2 (Wehrens et al., 2004a; Lehnart et al., 2008). This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.